Food and Drug Administration
Arthritis Advisory Committee
July 12, 2000
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Chimeric Monoclonal Antibody Against Human Tumor Necrosis Factor, Centocor Presentation pdf
Infliximab as a Treatment for Rheumatoid Arthritis - Prevention of Structural Damage, Dr Barbara Matthews, MD, FDA pdf
Radiographic Analyses of Disease Progression, Dr. Vibeke Strand, MD, Stanford U. School of Medicine htm ppt